This study was designed to compare 2 common techniques for anesthesia prior to facial filler injections to determine which anesthetic method resulted in less pain during filler injections and which was preferred for future treatments. Via a randomized, prospective, split-face design, one side was treated with topical lidocaine gel and the contralateral received nerve block injection(s) to the infraorbital and/or mental nerve with local anesthetic. Hyaluronic acid (HA) filler was used to treat cosmetic deformities of the nasolabial folds, upper, and/or lower lips. Patients were surveyed to quantify the subjective pain during (1) preprocedural anesthesia and (2) injection of HA filler. At 1 week, patients reported which side was perceived as less painful, and his or her future treatment preference. Forty-eight participants (46 women and 2 men) were enrolled. In all, 77% perceived the filler injections with anesthetic block(s) as less painful, 21% recorded injections on the side pretreated with topical anesthesia as less painful, and 2% perceived no difference. Of all participants, 56% preferred local anesthetic injections for future treatments, 33% chose topical anesthesia, and 10% (5 of 48) had no preference. Patients rated the treatment of HA injections after anesthetic block(s) as the least painful method. Although more than half of the patients preferred this modality, the posttreatment survey suggests that there may be other factors contributing to patients' preferences.
Introduction and Background
Facial cosmetic surgery is increasingly popular in modern societies including in the United States. 1 People who have a desire to look and feel youthful and physically attractive often turn to the facial cosmetic surgeon for treatments to enhance their facial appearance. The demand for outpatient, minimally invasive, and painless procedures has led to the increase in use of injectable facial fillers to treat mild facial defects, aging, and volume loss. 2, 3 Hyaluronic acid (HA) dermal filler products, such as Juvéderm (Allergan Plc, Irvine, California) and Restylane (Galderma, Lausanne, Switzerland), have become popular due to their safety, efficacy, and longevity, as well as their ability to be applied in the provider's office. 4 Hyaluronic acid is a naturally occurring, highly hygroscopic polysaccharide molecule that attracts and binds more than 1000 times its weight in water which converts it into viscous gel. 5 HA dermal fillers are derived from bacterial HA that is chemically treated for cross-linking to create a more stable molecule for longer duration of action and to create the injectable viscous gel form. 3, 4 They are nonimmunogenic due to the preserved structure of HA across species. 1, 5 When manufactured into dermal filler material, water is drawn into the HA molecules as they degrade in a process known as isovolumic degradation. Isovolumic degradation results in natural volume enhancement with greater longevity. 6 Allergan Plc currently manufactures 2 types of HA dermal filler (Juvéderm) indicated for injection into the mid to deep intradermal layer and (Voluma) indicated for deep (subcutaneous and/or supraperiosteal) injections in the cheek. Each has differing degrees of cross-linking; Juvéderm Ultra with 9% cross-linking and Juvéderm Ultra Plus with 11% cross-linking. Juvéderm specifically is a monophasic (meaning single treatment) monodensified gel, manufactured by a homogenization process called Hylacross technology unique to the product. 1 The newer formulations, approved by the Food and Drug Administration (FDA) in 2010, have XC added to the labeling indicating addition of 0.3% lidocaine. Incorporated lidocaine has been shown to decrease injection discomfort while maintaining the same properties as the original nonlidocaine-containing fillers. 1, [7] [8] [9] Restylane similarly comes in multiple degrees of cross-linking with incorporated lidocaine.
HA dermal fillers with lidocaine are indicated for treatment of volume loss in tear troughs, nasolabial folds, cheeks, upper lip, lower lip, oral commissure region, and marionette lines. 1, 3, 5, [10] [11] [12] Treatment with HA dermal fillers requires intradermal injections to deposit the fillers in the indicated tissue plane specific to the individual area of treatment and filler. 3, 5, 12, 13 The multiple facial injections required to achieve adequate treatment outcomes can be painful and ultimately may be a deterrent for some patients desiring treatment. In effort to mitigate the discomfort of the injection process, manufacturers of HA fillers have added lidocaine to some of their formulations, for example, Juvéderm XC and Restylane-L products. 9 The HA fillers with lidocaine added have been shown to have similar safety, efficacy, and longevity profiles as their non-lidocaine-containing counterparts. 9, 11, 12, 14, 15 Providers commonly use an additional method of local anesthesia in attempt to make treatment more tolerable. Some examples of these local anesthesia methods are ice to the skin prior to treatment, use of topical anesthetic such as 20% benzocaine, 6% lidocaine, and 4% tetracaine vs lidocaine/tetracaine 7%/7% cream vs lidocaine 4% to 5% gel. In addition, infiltration of local anesthetic via nerve block injections with 2% lidocaine with 1:100 000 epinephrine [16] [17] [18] [19] are frequently used. The authors' intent for this trial was to determine the pain on injection of HA fillers with 2 common types of anesthetic and to report which method is preferred among the facial cosmetic surgery patient population. The authors hypothesized that patients would prefer local anesthetic blocks prior to facial filler injection. The specific aim of the study was to provide surgeons with insight into patient preference for preprocedural anesthetic to optimize patient comfort and satisfaction. This is the first split-face, randomized trial to consider patient preference for adjunctive anesthetic method rather than just quantifying pain with visual analog scale (VAS).
Methods and Materials
To address the purpose of the trial, the authors designed a randomized, split-face clinical trial to evaluate patient preference for anesthetic method prior to the injection of facial cosmetic injectable fillers from September 2014 to July 2015. A total of 50 participants with facial volume loss or cosmetic defects seeking treatment to improve their facial aesthetics were enrolled from the Oral & Maxillofacial Surgery Clinic at David Grant USAF Medical Center, Travis AFB, California. This study was approved by the Institutional Review Board (IRB) at David Grant Medical Center, and all participants signed an informed consent agreement prior to the study. Each participant completed a total of 3 appointments, consisting of an initial evaluation appointment, treatment appointment, and 1-week posttreatment follow-up. At the initial appointment, the participants were evaluated for facial volume loss and presence of skin laxity or facial rhytids and deep grooves. Treatment goals, location, and expectations were established; medical and surgical history reviewed; and informed consent obtained. Documentation about the study was provided to each participant to allow for their decision to participate in the elective trial. Participants were required to be at least 18 years old with deep nasolabial folds and/or deficient upper and/or lower lip volume and architecture. Participants should not have had HA filler within the last 6 months, have allergies to lidocaine or HA, have significant coronary artery disease, or be currently pregnant or nursing. Detailed inclusion and exclusion criteria for the trial are listed in Table 1 .
The primary predictor variable is the anesthetic technique: local anesthesia nerve block injections vs topical anesthesia, which are described in detail in this section. For the treatment appointment, all local anesthesia and HA filler were administered by an attending surgeon (R.M.D) or chief resident surgeon(s) trained in facial cosmetic filler injections and who were also familiar with the trial protocols. Each procedure began with a coin toss to randomize which side of the face was to be anesthetized with local anesthesia nerve blocks or topical anesthetic. The head side of the coin coincided with local anesthesia nerve block(s) on the patient's right side. The tail of the coin designated the patient's left side for local anesthetic injections. The left side of the face was always treated first, regardless of the method of local anesthesia. The amount of time for each anesthesia method to properly exert effect was timed by a third party, familiar with protocol. On the local anesthesia nerve block side, the provider placed a small amount of topical 20% benzocaine anesthetic gel on the oral mucosa over the proposed site(s) of the intraoral nerve blocks and allowed the gel to remain in place for 5 minutes per manufacturer's recommendation. One milliliter of 2% lidocaine with 1:100 000 epinephrine was then injected via a standard dental aspirating syringe with 1½″ × 27-gauge needle over 1 minute to anesthetize the infraorbital and/or the mental nerve depending on the areas designated for treatment. For the nasolabial fold and upper lip, the infraorbital nerve was blocked, and for the lower lip, the mental nerve was blocked. The HA filler injections were not commenced until at least 10 minutes had elapsed and profound anesthesia to the affected area was obtained. On the contralateral side, roughly 1 to 2 mL of 4% lidocaine (Topicaine; ESBA Laboratories, Jupiter, Florida) gel was liberally placed over the area to be treated with HA filler for 20 minutes prior to injection per manufacturer's recommendations. Patients were asked to complete a VAS pain assessment for the right and left side of their face for the application phase of each type of anesthetic. Appropriate anesthesia was assessed prior to initiating HA filler injections by applying pinpoint pressure to the site of filler injections. If insufficient anesthesia was obtained, more time was given for onset of topical anesthesia. This process was repeated until adequate anesthesia was achieved. Per the protocol, in the event where adequate anesthesia was not achieved with the topical lidocaine gel, local anesthetic nerve block was completed and the patient was excluded from the trial; this was never encountered.
The provider completed the left-side nasolabial fold and/ or lip(s) with Juvéderm XC injections followed by right-side nasolabial and/or lip(s) injections with Juvéderm XC. A standard, injection technique in an intradermal plane was used with two 30-gauge needles provided by the manufacturer in the packaging. The injection technique was provider and injection-site dependent. The number of injections to each site was recorded by the third-party observer. Patients were asked to exclude any midline injections to the lips from their assessment of right-or left-sided discomfort. At no point during the study did we deviate from the standard of care for both pretreatment anesthesia and treatment with cosmetic HA dermal fillers. The Juvéderm Ultra XC or Juvéderm Ultra Plus XC used was based on the discretion of provider for treatment of the specific cosmetic facial deformity. These 2 formulations of Juvéderm XC contain identical concentrations of lidocaine (0.3%) and are considered equivalent in anesthetic value. Immediately upon completion of the procedure, VAS pain assessment was completed for the right and left sides (Figure 1) .
The primary outcome variables were the patient's level of pain during application of adjunctive anesthesia, level of pain during injection of facial cosmetic fillers and finally, each patient's preference for anesthesia at future treatments. The pain levels were accessed at the treatment appointment, and patients' preferences were annotated at the 1-week follow-up appointment. At the 1-week posttreatment follow-up appointment, patients were asked which side of their face they perceived the HA filler injections to be less painful. They were also asked which method of local anesthesia they would prefer if they were to have the same procedure repeated in the future. The options were topical anesthesia, local anesthesia nerve blocks, or no preference. All data was collected by an unbiased third party from the Clinical Investigation Facility at David Grant Medical Center and submitted for analysis. The median VAS pain score of the local anesthetic was compared with the topical anesthetic using the paired sign-rank test. Statistical significance was defined as P < .05. In this comparison, P = .000001. A chisquare goodness-of-fit test was used to test the null hypothesis that, theoretically, the frequencies of the preference for each method of local anesthesia would be the same. The data were analyzed with P value of .0005 to support a statistically significant difference in patients' preferences for a type of local anesthesia prior to treatment with HA fillers.
Results
A total of 50 patients were initially enrolled in the trial. Two patients dropped out of the trial, leaving a total of 48 patients (46 women and 2 men) with a mean age of 52 years (range, 22-81 years), all of whom met the inclusion criteria (Table 1) . Each patient received HA dermal filler treatments to the nasolabial fold (NLF), upper lip (UL), and/or lower lip (LL) regions specific to the patient's cosmetic needs. For the anesthetic method prior to injection, the median VAS pain score of the local anesthetic was compared with the topical anesthetic using the paired sign-rank test. Pain associated with application of topical anesthesia using the VAS (0-10) was 0.06 NLF/ UL, 0.11 LL. Pain associated with local anesthesia nerve block using the VAS was 2.14 for infraorbital nerve block (intraoral approach) and 1.89 for mental nerve block (intraoral approach) ( Table 2) . Pain associated with HA filler injections on the side of the face treated with local anesthesia nerve blocks using the VAS was 0.76 NLF, 0.89 UL, 1.47 LL (Figure 2 ). Pain associated with HA filler injections on the side of the face treated with topical anesthesia using the VAS was 2.81 NLF, 3.67 UL, 4.38 LL (Figure 2 ). In all, 77% (37 of 48) of the patients perceived treatment in the areas of local anesthesia nerve block as less painful, 21% (10 of 48) of the patients perceived treatment in the areas of topical anesthesia as less painful, and 2% (1 of 48) of patients perceived no difference in pain level during treatment of either side of their face with HA filler (Figure 3) .
In regard to patient preference, 56% (27 of 48) chose the local anesthesia nerve block as their preferred method of local anesthesia for future treatments, 33% (16 of 48) chose topical anesthesia, and 10% (5 of 48) had no preference (Figure 3) . Statistical significance was defined as P < .05 and in this comparison, P = .00001. The results were highly significant leading to rejection of the null hypothesis that there is no difference between patient preference for the 2 methods of local anesthesia. In addition, a chi-square goodness-of-fit test was used to test the null hypothesis that, theoretically, the frequencies of preference (topical anesthesia vs local anesthesia vs no preference) are the same. The chi-square test analysis was 15.28 with P = .0005.
The results from this trial may influence the practice of any provider using HA-injectable cosmetic fillers for treatment of minor facial cosmetic defects or volume deficiency in the outpatient setting. The use of HA fillers which contain lidocaine have been shown to have similar efficacy, safety, and longevity as HA fillers without, but increase in patient and provider satisfaction with their use allows them to become the new standard in filler material. [20] [21] [22] Additional anesthesia (topical and local anesthetic) prior to treatment has been shown in previous studies to decease overall pain scores associated with the injections of the filler material. This is the first randomized, split-face trial giving insight into the patient's overall preference for anesthetic method. It uses both the data from perceived pain levels comparing 2 modalities of anesthetic and the patient's subjective preference to evaluate overall pain, site-specific pain, pain with application of the anesthetic, and finally whether these outcomes affect the patient's future preferred technique.
One would assume that patients would prefer the anesthetic method that caused the least amount of pain during the treatment; however, 56% (9 of 16) of the patients who chose topical anesthesia as preferred method for future treatments perceived the local anesthesia nerve blocks as less painful. This suggests that there are factors other than pain contributing to a person's preference for local or topical anesthesia prior to facial filler injections. Some patients stated that they do not want to be encumbered by posttreatment paresthesia. In addition, a person may be fearful of injections in general and the thought of an additional injection, albeit one to anesthetize their treatment site, may be psychologically difficult to overcome. Many people have an aversion to "dental injections," and the association of the nerve block anesthetic injections used for dental treatments may be a factor in the patient preference for topical anesthesia only. Furthermore, the needle used to administer the local anesthetic blocks in this study was much longer and used intraorally which is possibly more intimidating to someone than the small needles used to administer the cosmetic filler material. The provider's experience level with local anesthetic nerve blocks and cosmetic filler injection techniques may certainly play a role in patient perceived pain. The delivery method of the HA filler (needle vs cannula) and the location of the filler are other variables that may contribute to the patients' preference. It is difficult to speculate all the factors involved in the patients' preferences, but this study suggests that pain is not the only factor driving their choice for local anesthesia. The treatment areas included in this trial comprised of the nasolabial folds and the upper and lower lips. A noteworthy and incidental finding in this study is that the level of pain or discomfort varies with each area of treatment. The least painful area of treatment for patients was the nasolabial fold, followed closely by upper lip, then the lower lip which was the most painful area for HA filler injections. Regardless of the type of local anesthesia used, the nasolabial folds appear to have the least discomfort when treated with injectable fillers with a mean VAS score of 2.81 and 0.76, respectively, for topical gel and local anesthesia nerve blocks. This is more than 1.5 times less painful than the mean VAS recorded for lower lip treatment injections regardless of local anesthesia method. This result may be due to increased difficulty for profound anesthesia of the lips or simply due to the extreme sensitivity of the lips compared with the skin of the midface.
Interestingly, the authors found that after administration of local anesthesia nerve blocks, lips became ptotic compared with the topical anesthesia side. Facial filler was applied as symmetrically as possible to the treatment areas, but occasionally a "touch up" treatment was required at the posttreatment follow-up to achieve better symmetry once reevaluated with normal facial tone.
Eleven of the 48 (22.9%) patients received additional filler at the follow-up appointment. Five of the 11 patients (45.5%) who had additional filler received it to increase volume of the upper and lower lips. These patients reported no complaints of asymmetry at the 1-week follow-up but simply wanted fuller lips. Three of the 48 (6.25%) received additional HA filler in the upper lip on the side of local infiltration due to mild asymmetry. In addition, 3 of the 48 participants (6.25%) received additional filler on the side opposite the local infiltration (topical side). One was due to under injection on the topical side due to a hematoma at the time of initial HA filler injection, and 2 were in the nasolabial folds on the side opposite the local infiltration to further efface the fold.
Conclusion and Discussion
The use of injectable filler materials for treatment of minor cosmetic facial defects has become increasingly popular. The administration of the injectable filler can be a painful experience to the cosmetic patient wishing to improve their facial aesthetics. To minimize patient discomfort, anesthetic is often used in the forms of topical anesthesia or local anesthetic nerve blocks prior to injectable facial filler treatment.
Our study not only attempted to quantify the amount of discomfort during HA filler treatment after 2 commonly used methods of anesthetic, but also to assess the patients' preferences for future treatments. This trial allows the provider to better educate their patients and allow the patient to make the most informed decision on which type of anesthesia may provide the best experience for each individual. In their pursuit to provide the most comfortable and pleasant experience for the cosmetic facial filler patient, the provider should be proficient in techniques to administer both types of anesthesia, topical and local anesthetic nerve blocks, when using injectable facial fillers in an office-based or outpatient setting.
This study was the first to the authors' knowledge which set forth to determine patients' preferences for anesthetic modalities prior to facial filler injections. This study will better aid the surgeon in preoperative consultation to inform each patient of the expected level of injection pain thus allowing for individualized treatment. A follow-up study is planned to compare the preferred method from this study vs the use of microcannulas with topical anesthetic for injectable fillers.
